Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

News Features

Year in Review: Payment Fights, Wearables, Burnout Defined Cardiology Practice in 2019

Caitlin E. Cox

December 17, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2019

Shelley Wood

November 29, 2019

News Conference News VIVA 2019

Future Pulmonary Embolism Interventions: Wild West or Working Together?

L.A. McKeown

November 14, 2019

News Conference News VIVA 2019

Calcium Conundrum: New Scores, Research Aim to Boost Outcomes in PAD Interventions

L.A. McKeown

November 13, 2019

News Conference News VIVA 2019

Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel

L.A. McKeown

November 08, 2019

News Conference News VIVA 2019

Clinicians Get Real on Radiation: ‘Don’t Do Dumb Things’

L.A. McKeown

November 07, 2019

News Conference News HFSA 2019

Virtual Doctor Visits Reduce Missed Appointments After HF Hospitalizations: ViV-HF

L.A. McKeown

September 23, 2019

News Opinion Off Script

Off Script: Through ‘Paclitaxelgate,’ Some Upsides to Uncertainty

Sahil Parikh, MD

July 29, 2019

News Daily News

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

L.A. McKeown

June 10, 2019

News Conference News SCAI 2019

Paclitaxel DCBs and CHIP: SCAI Kicks Off With Two Hot-Potato Topics

Yael L. Maxwell

May 21, 2019

News Daily News

Vici Venous Stent Receives FDA Approval for Iliofemoral Obstructive Disease

L.A. McKeown

May 06, 2019

News Conference News ACC 2019

My Takeaways From ACC 2019: Breaking With Embargoes? Despite the Drama, Embargoes Set to Stay

Shelley Wood

April 05, 2019

News Daily News

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

L.A. McKeown

March 15, 2019

News Conference News CRT 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

L.A. McKeown

March 06, 2019

News Daily News

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

L.A. McKeown

March 01, 2019

News Daily News

‘Inadvertent Reversal’ of Late Mortality Data Flips Advantage From Paclitaxel Zilver PTX Stent in PAD to PTA

L.A. McKeown

February 20, 2019

News Daily News

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

L.A. McKeown

February 13, 2019

News CV Team Pro

Featured Cath Lab Pro: Vivian Tamara

January 28, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

Advertisement

Year in Review: Payment Fights, Wearables, Burnout Defined Cardiology Practice in 2019

TCTMD’s Top 10 Most Popular Stories for November 2019

Future Pulmonary Embolism Interventions: Wild West or Working Together?

Calcium Conundrum: New Scores, Research Aim to Boost Outcomes in PAD Interventions

Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel

Clinicians Get Real on Radiation: ‘Don’t Do Dumb Things’

Virtual Doctor Visits Reduce Missed Appointments After HF Hospitalizations: ViV-HF

Off Script: Through ‘Paclitaxelgate,’ Some Upsides to Uncertainty

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

Paclitaxel DCBs and CHIP: SCAI Kicks Off With Two Hot-Potato Topics

Vici Venous Stent Receives FDA Approval for Iliofemoral Obstructive Disease

My Takeaways From ACC 2019: Breaking With Embargoes? Despite the Drama, Embargoes Set to Stay

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

‘Inadvertent Reversal’ of Late Mortality Data Flips Advantage From Paclitaxel Zilver PTX Stent in PAD to PTA

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

Featured Cath Lab Pro: Vivian Tamara

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content